Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

November 3, 2017: By Jon Swedien


The US FDA has approved the new drug application (NDA) for Bausch + Lomb’s Vyzulta for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, parent Valeant announced Nov. 2.

Vyzulta (latanoprostene bunod ophthalmic solution 0.024%), a nitric oxide-donating prostaglandin analog, is a once daily monotherapy.

Valeant CEO Joseph Papa said the company plans to launch Vyzulta by the end of 2017.

Nicox licensed Vyzulta to Bausch + Lomb on a global basis in 2010. As a result of the approval, Nicox will receive $17.5 million from Bausch + Lomb, and Nicox will make a $15 million payment to Pfizer under a previous license agreement, Valeant said.

Vyzulta’s approval was delayed twice because of problems at Bausch + Lomb’s manufacturing plant in Tampa, Florida. The FDA held up several ophthalmic drug candidates over plant concerns in 2016 and 2017.

Valeant resolved its issues, allowing the regulatory process to proceed.

In multiple clinical studies, Vyzulta outperformed timolol and latanoprost in lowering IOP, the company said.

Previously known as Vesneo, the drug was renamed Vyzulta in January.

The most common ocular adverse events associated with Vyzulta include conjunctival hyperemia, eye irritation, eye pain, and instillation site pain, Valeant said. Increased pigmentation of the iris and periorbital tissue and growth of eyelashes also can occur, Valeant said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023